EAACI guidelines on allergen immunotherapy: prevention of allergy

Allergic diseases are common and frequently coexist. Allergen immunotherapy (AIT) is a disease-modifying treatment for IgE-mediated allergic disease with effects beyond cessation of AIT that may include important preventive effects. The European Academy of Allergy and Clinical Immunology (EAACI) has...

Full description

Saved in:
Bibliographic Details
Main Authors: Halken, Susanne (Author) , Pfaar, Oliver (Author)
Format: Article (Journal)
Language:English
Published: 13 September 2017
In: Pediatric allergy and immunology
Year: 2017, Volume: 28, Issue: 8, Pages: 728-745
ISSN:1399-3038
DOI:10.1111/pai.12807
Online Access:Verlag, Volltext: http://dx.doi.org/10.1111/pai.12807
Verlag, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/pai.12807
Get full text
Author Notes:Susanne Halken, Desiree Larenas‐Linnemann, Graham Roberts, Moises A. Calderón, Elisabeth Angier, Oliver Pfaar, Dermot Ryan, Ioana Agache, Ignacio J. Ansotegui, Stefania Arasi, George Du Toit, Montserrat Fernandez‐Rivas, Roy Geerth van Wijk, Marek Jutel, Jörg Kleine‐Tebbe, Susanne Lau, Paolo M. Matricardi, Giovanni B. Pajno, Nikolaos G. Papadopoulos, Martin Penagos, Alexandra F. Santos, Gunter J. Sturm, Frans Timmermans, R. van Ree, Eva-Maria Varga, Ulrich Wahn, Maria Kristiansen, Sangeeta Dhami, Aziz Sheikh, Antonella Muraro

MARC

LEADER 00000caa a2200000 c 4500
001 1575268167
003 DE-627
005 20230427042904.0
007 cr uuu---uuuuu
008 180517s2017 xx |||||o 00| ||eng c
024 7 |a 10.1111/pai.12807  |2 doi 
035 |a (DE-627)1575268167 
035 |a (DE-576)505268167 
035 |a (DE-599)BSZ505268167 
035 |a (OCoLC)1341009675 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Halken, Susanne  |e VerfasserIn  |0 (DE-588)1159733201  |0 (DE-627)102241349X  |0 (DE-576)505268213  |4 aut 
245 1 0 |a EAACI guidelines on allergen immunotherapy  |b prevention of allergy  |c Susanne Halken, Desiree Larenas‐Linnemann, Graham Roberts, Moises A. Calderón, Elisabeth Angier, Oliver Pfaar, Dermot Ryan, Ioana Agache, Ignacio J. Ansotegui, Stefania Arasi, George Du Toit, Montserrat Fernandez‐Rivas, Roy Geerth van Wijk, Marek Jutel, Jörg Kleine‐Tebbe, Susanne Lau, Paolo M. Matricardi, Giovanni B. Pajno, Nikolaos G. Papadopoulos, Martin Penagos, Alexandra F. Santos, Gunter J. Sturm, Frans Timmermans, R. van Ree, Eva-Maria Varga, Ulrich Wahn, Maria Kristiansen, Sangeeta Dhami, Aziz Sheikh, Antonella Muraro 
264 1 |c 13 September 2017 
300 |a 18 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 17.04.2018 
520 |a Allergic diseases are common and frequently coexist. Allergen immunotherapy (AIT) is a disease-modifying treatment for IgE-mediated allergic disease with effects beyond cessation of AIT that may include important preventive effects. The European Academy of Allergy and Clinical Immunology (EAACI) has developed a clinical practice guideline to provide evidence-based recommendations for AIT for the prevention of (i) development of allergic comorbidities in those with established allergic diseases, (ii) development of first allergic condition, and (iii) allergic sensitization. This guideline has been developed using the Appraisal of Guidelines for Research & Evaluation (AGREE II) framework, which involved a multidisciplinary expert working group, a systematic review of the underpinning evidence, and external peer-review of draft recommendations. Our key recommendation is that a 3-year course of subcutaneous or sublingual AIT can be recommended for children and adolescents with moderate-to-severe allergic rhinitis (AR) triggered by grass/birch pollen allergy to prevent asthma for up to 2 years post-AIT in addition to its sustained effect on AR symptoms and medication. Some trial data even suggest a preventive effect on asthma symptoms and medication more than 2 years post-AIT. We need more evidence concerning AIT for prevention in individuals with AR triggered by house dust mites or other allergens and for the prevention of allergic sensitization, the first allergic disease, or for the prevention of allergic comorbidities in those with other allergic conditions. Evidence for the preventive potential of AIT as disease-modifying treatment exists but there is an urgent need for more high-quality clinical trials. 
650 4 |a AGREE II 
650 4 |a allergen immunotherapy 
650 4 |a allergic diseases 
650 4 |a allergic rhinitis 
650 4 |a allergy 
650 4 |a asthma 
650 4 |a atopic dermatitis/eczema 
650 4 |a atopy 
650 4 |a prevention 
650 4 |a sensitization 
700 1 |a Pfaar, Oliver  |d 1972-  |e VerfasserIn  |0 (DE-588)12385900X  |0 (DE-627)706454049  |0 (DE-576)293913099  |4 aut 
773 0 8 |i Enthalten in  |t Pediatric allergy and immunology  |d Oxford [u.a.] : Wiley-Blackwell, 1990  |g 28(2017), 8, Seite 728-745  |h Online-Ressource  |w (DE-627)320471403  |w (DE-600)2008584-9  |w (DE-576)091169631  |x 1399-3038  |7 nnas  |a EAACI guidelines on allergen immunotherapy prevention of allergy 
773 1 8 |g volume:28  |g year:2017  |g number:8  |g pages:728-745  |g extent:18  |a EAACI guidelines on allergen immunotherapy prevention of allergy 
856 4 0 |u http://dx.doi.org/10.1111/pai.12807  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u https://onlinelibrary.wiley.com/doi/abs/10.1111/pai.12807  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20180517 
993 |a Article 
994 |a 2017 
998 |g 12385900X  |a Pfaar, Oliver  |m 12385900X:Pfaar, Oliver  |d 60000  |d 62100  |e 60000PP12385900X  |e 62100PP12385900X  |k 0/60000/  |k 1/60000/62100/  |p 6 
999 |a KXP-PPN1575268167  |e 3009717997 
BIB |a Y 
SER |a journal 
JSO |a {"type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"doi":["10.1111/pai.12807"],"eki":["1575268167"]},"physDesc":[{"extent":"18 S."}],"relHost":[{"type":{"bibl":"periodical","media":"Online-Ressource"},"pubHistory":["1.1990 -"],"language":["eng"],"disp":"EAACI guidelines on allergen immunotherapy prevention of allergyPediatric allergy and immunology","recId":"320471403","note":["Gesehen am 26.07.07"],"part":{"text":"28(2017), 8, Seite 728-745","volume":"28","year":"2017","pages":"728-745","extent":"18","issue":"8"},"id":{"eki":["320471403"],"zdb":["2008584-9"],"doi":["10.1111/(ISSN)1399-3038"],"issn":["1399-3038"]},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Pediatric allergy and immunology","title":"Pediatric allergy and immunology"}],"origin":[{"publisher":"Wiley-Blackwell ; Munksgaard ; Blackwell","dateIssuedDisp":"1990-","dateIssuedKey":"1990","publisherPlace":"Oxford [u.a.] ; Copenhagen ; Oxford [u.a.]"}]}],"note":["Gesehen am 17.04.2018"],"recId":"1575268167","name":{"displayForm":["Susanne Halken, Desiree Larenas‐Linnemann, Graham Roberts, Moises A. Calderón, Elisabeth Angier, Oliver Pfaar, Dermot Ryan, Ioana Agache, Ignacio J. Ansotegui, Stefania Arasi, George Du Toit, Montserrat Fernandez‐Rivas, Roy Geerth van Wijk, Marek Jutel, Jörg Kleine‐Tebbe, Susanne Lau, Paolo M. Matricardi, Giovanni B. Pajno, Nikolaos G. Papadopoulos, Martin Penagos, Alexandra F. Santos, Gunter J. Sturm, Frans Timmermans, R. van Ree, Eva-Maria Varga, Ulrich Wahn, Maria Kristiansen, Sangeeta Dhami, Aziz Sheikh, Antonella Muraro"]},"origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"13 September 2017"}],"person":[{"role":"aut","display":"Halken, Susanne","given":"Susanne","family":"Halken"},{"display":"Pfaar, Oliver","given":"Oliver","family":"Pfaar","role":"aut"}],"language":["eng"],"title":[{"title_sort":"EAACI guidelines on allergen immunotherapy","subtitle":"prevention of allergy","title":"EAACI guidelines on allergen immunotherapy"}]} 
SRT |a HALKENSUSAEAACIGUIDE1320